• O Guyonvarch, L Vaillant, T Hanslik, T Blanchon, E Rouveix, and V Supervie.
• Inserm, unité mixte de recherche en santé 1136, Institut Pierre Louis d'épidémiologie et de Santé publique, Sorbonne université, 27, rue de Chaligny, 75012 Paris, France. Electronic address: ophelie.guyonvarch@gmail.com.
• Rev Med Interne. 2021 Apr 1; 42 (4): 275-280.

AbstractPre-exposure prophlaxis (PrEP) is the use of antiretroviral drugs by uninfected people to prevent human immunodeficiency virus (HIV) infection. PrEP is used by people who are at substantial risk of being exposed to HIV. Numerous clinical trials have confirmed its effectiveness in reducing HIV acquisition and PrEP has been approved and allowed in several countries including France. However, PrEP uptake remains low as concerns about increase in sexual risk behaviour with PrEP use in the wake of a growing epidemic of sexually transmitted infections, and fear of drug resistance have been expressed. As a result, the difference between the proportion of people on PrEP and the proportion of people who would be very likely to use PrEP if they could access it -otherwise known as the PrEP gap- remains high. Nowadays, studies continue to explore long-term effects of PrEP as well as expand the array of available technologies and regimens.Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

17 keywords...

hide…